Myeloproliferative Disease Follow-up

  • Author: Haleem J Rasool, MD, FACP; Chief Editor: Emmanuel C Besa, MD   more...
 
Updated: Nov 17, 2011
 

Complications

  • Patients are at risk of both thrombotic and hemorrhagic events.
    • Thrombotic and hemorrhagic events are particularly common in polycythemia vera (PV) and essential thrombocythemia (ET). Thrombosis is the cause of death in 30-40% of patients.
    • A particularly serious thrombotic event that may be associated with polycythemia vera is Budd-Chiari syndrome, which is due to hepatic venous or inferior venal caval thrombosis.
  • Patients are at risk of developing secondary acute leukemia from their underlying disorder as well as their treatment.
 
Contributor Information and Disclosures
Author

Haleem J Rasool, MD, FACP  Hematologist/Oncologist, Department of Oncology, Franciscan Skemp Healthcare

Haleem J Rasool, MD, FACP is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine and American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Koyamangalath Krishnan, MD, FRCP, FACP  Paul Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine and Chief of Hematology-Oncology, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, and Royal College of Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Troy H Guthrie, Jr, MD  Director of Cancer Institute, Baptist Medical Center

Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association

Disclosure: Nothing to disclose.

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD  Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences

Disclosure: Nothing to disclose.

References

  1. Vardiman JW. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2299-2300. [Medline]. [Full Text].

  2. Baxter EJ, Scott LM, Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. Mar 19-25 2005;365(9464):1054-61. [Medline].

  3. James C, Ugo V, Le Couedic JP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. Apr 28 2005;434(7037):1144-8. [Medline].

  4. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617) and leukemic transformation in myelofirbrosis with myeloid metaplasia. Leuk Res. 2006/11;30 (11):1457-60.

  5. Anand S, Stedham F, Beer P, et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood. Jul 7 2011;118(1):177-81. [Medline].

  6. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. Jul 14 2011;118(2):401-8. [Medline].

  7. Donato NJ, Talpaz M. Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin Cancer Res. Aug 2000;6(8):2965-6. [Medline].

  8. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. Jun 10 2011;29(17):2410-5. [Medline]. [Full Text].

  9. O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. Mar 13 2003;348(11):994-1004. [Medline].

  10. Kaplan ME, Mack K, Goldberg JD. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol. Jul 1986;23(3):167-71. [Medline].

  11. Doll DC, Gabrail NY, List AF. Introduction: myeloproliferative disorders. Semin Oncol. Aug 1995;22(4):305-6. [Medline].

  12. Faderl S, Kantarjian HM, Talpaz M. New treatment approaches for chronic myelogenous leukemia. Semin Oncol. Oct 2000;27(5):578-86. [Medline].

  13. Froom P, Elmalah I, Braester A. Clodronate in myelofibrosis: a case report. Am J Med Sci. Feb 2002;323(2):115-6. [Medline].

  14. Johansson P, Kutti J, Andreasson B. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med. Aug 2004;256(2):161-5.

  15. Kralovics R, Passamonti F, Buser AS. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. Apr 28 2005;352(17):1779-90. [Medline].

  16. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris). Mar 2001;49(2):164-6. [Medline].

  17. Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. Apr 2005;7(4):387-97. [Medline].

  18. O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program). 2004;146-62.

  19. Pardanani A, Brockman SR, Paternoster SF. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. Nov 15 2004;104(10):3038-45. [Medline]. [Full Text].

  20. Staerk J, Kallin A, Demoulin JB. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation:CROSS-TALK WITH IGF1 RECEPTOR. J Biol Chem. Dec 23 2005;280(51):41893-9.

  21. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med. Aug 1 2000;109(2):141-9. [Medline].

 
Previous
Next
 
Peripheral smear of a patient with chronic myelogenous leukemia (CML) shows leukocytosis with extreme left shift and basophilia.
Peripheral smear of a patient with chronic myelogenous leukemia (CML) in blastic phase shows several blasts.
Peripheral smear of a patient with essential thrombocythemia (ET) shows markedly increased number of platelets. Some of the platelets are giant (arrow).
Peripheral smear of a patient with agnogenic myeloid metaplasia (myelofibrosis) shows leukoerythroblastosis. This photomicrograph also shows giant platelets.
Photomicrograph of a peripheral smear of a patient with agnogenic myeloid metaplasia (myelofibrosis) shows findings of leukoerythroblastosis, giant platelets, and few teardrop cells.
Table. Comparison of FAB and WHO Classifications of Chronic Myeloproliferative Diseases.
FAB WHO
Chronic myelogenous leukemiaChronic myelogenous leukemia
Polycythemia veraPolycythemia vera
Essential thrombocythemiaEssential thrombocythemia
Agnogenic myeloid metaplasia/myelofibrosisChronic idiopathic myelofibrosis
...Chronic neutrophilic leukemia
...Chronic eosinophilic leukemia/hypereosinophilic syndrome
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.